| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15110097 | IVTH | 0.00001 - 0.001 M | 0.00001 - 0.001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:17904329 | IVR | 1000 mg/kg/day | 1000 mg/kg/day | Uterotrophic effect | Reproductive endocrine-mediated perturbations |
| PMID:22531466 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:24563381 | IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increase in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increased progestagens levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| PMID:26186136 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:26751127 | IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:28628672 | IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:28735473 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:28808208 | IVTH | 0.0000001 - 0.00001 M | 0.000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.0000001 - 0.00001 M | 0.000001 - 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:30120946 | IVR | 0.005 mg/L | - | No significant effects observed | - |
| IVR | 0.025 mg/L | 0.025 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| PMID:30613871 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects cell metabolism | Metabolic endocrine-mediated perturbations |
| PMID:30823348 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Oxidative stress in liver in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased triglycerides level in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects glycogen metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased hepatic glycogen levels in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| PMID:30871434 | IVR | 25 mg/kg/day | - | No significant effects observed | - |
| IVR | 5 mg/kg/day | - | No significant effects observed | - | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations | |
| PMID:31388671 | IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:31601247 | IVTH | 0.000001 M | 0.000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVTH | 0.00000001 M | 0.00000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:31875995 | IVTH | 0.000065 M | 0.000065 M | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| PMID:9449681 | IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.